Skip to main content
SpringerLink
Log in

Prävention der Atherosklerose bei gefäßchirurgischen Patienten

The prevention of atherosclerosis in vascular surgery patients

  • Arteriosklerose und Screening
  • Published:
Gefässchirurgie Aims and scope Submit manuscript

Zusammenfassung

Wie in nur wenigen anderen Wissenschaftsbereichen hat die kardiovaskuläre Prävention in den letzten Jahren eine enorme Wissenserweiterung erfahren. Durch eine konsequente Umsetzung der Studienergebnisse in der Primär- und Sekundärprävention könnte ein Großteil aller vaskulären Ereignisse in Mitteleuropa verhindert werden. Die aktuelle Abhandlung fasst den derzeitigen Wissensstand in der Vorsorge der Atherosklerose bei gefäßchirurgischen Patienten und die daraus abzuleitenden praktischen Empfehlungen zusammen. Neben den gut etablierten Risikofaktoren wie Hypertonie, Diabetes, Hypercholesterolämie, Rauchen und Bewegungsarmut werden auch neue mögliche Risikokonditionen wie Hyperhomocysteinämie, Körpereisenüberladung, intravaskuläre Inflammation und chronische Infektion diskutiert. Kurz resümiert werden der Einsatz von ACE-Hemmern und Statinen sowie die Indikation von Thrombozytenfunktionshemmern und Antikoagulanzientherapie. Ein weiterer Schwerpunkt liegt in der Darstellung gesicherter Ernährungsempfehlungen.

Abstract

In recent years, research on cardiovascular prevention has been among the fields with the most pronounced medical progress. The majority of vascular events can be prevented by observing currently available prevention guidelines. This review summarizes the most compelling studies and meta-analyses on this issue and lists the main consequences and resulting recommendations. Apart from the classic risk factors, there is a special focus on new risk concepts including the toxic effects of homocysteine, the ‘iron hypothesis’, and the intriguing issues of inflammation and chronic infection. The use of ACE inhibitors and statins, the indications for anti-aggregatory drugs and anticoagulation therapy, as well as dietary guidelines, will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Anderson GL, Limacher M, Assaf AR et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291: 1701–1712

    CAS  PubMed  Google Scholar 

  2. Anonym (1997) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157: 2413–2446

    Article  PubMed  Google Scholar 

  3. Beral V, Banks E, Reeves G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360: 942–944

    Article  PubMed  Google Scholar 

  4. Bonora E, Kiechl S, Oberhollenzer F et al. (2000) Impaired glucose tolerance, type 2 diabetes mellitus and carotid atherosclerosis. Prospective results from the Bruneck Study. Diabetologia 43: 156–164

    Article  CAS  PubMed  Google Scholar 

  5. Brand FN, Abbott RD, Kannel WB (1989) Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes 38: 504–509

    CAS  PubMed  Google Scholar 

  6. Cannon CP, Braunwald E, McCabe CH et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504

    Article  CAS  PubMed  Google Scholar 

  7. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

    Article  PubMed  Google Scholar 

  8. Dahlof B, Devereux RB, Dahlof B et al. (2002) LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003

    Article  CAS  PubMed  Google Scholar 

  9. Danesh J, Wheeler JG, Hirschfield GM et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387–1397

    Article  CAS  PubMed  Google Scholar 

  10. Fowkes FG, Housley E, Riemersma RA et al. (1992) Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 135: 331–340

    CAS  PubMed  Google Scholar 

  11. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393

    Article  PubMed  Google Scholar 

  12. Gasecki AP, Eliasziw M, Ferguson GG, Hachinski V, Barnett HJ (1995) Long-term prognosis and effect of endarterectomy in patients with symptomatic severe carotid stenosis and contralateral carotid stenosis or occlusion: results from NASCET. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. J Neurosurg 83: 778–782

    CAS  PubMed  Google Scholar 

  13. Gillum RF, Mussolino ME, Ingram DD (1996) Physical activity and stroke incidence in women and men: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 143: 860–869

    CAS  PubMed  Google Scholar 

  14. GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354: 447–455

    Article  PubMed  Google Scholar 

  15. Goldstein LB, Adams R, Becker K, et al. (2002) Primary prevention of stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 103: 163–182

    Google Scholar 

  16. Hacke W, Kaste M, Olsen TS, Orgogozo JM, Bogousslavsky J (2001) Recommendations of the European Stroke Initiative for management and treatment of stroke. Nervenarzt 72: 807–819

    Article  CAS  PubMed  Google Scholar 

  17. Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755–1762

    Article  CAS  PubMed  Google Scholar 

  18. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22

    Article  PubMed  Google Scholar 

  19. Hess H, Mietaschk A (1985) Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet I: 415–419

    Article  Google Scholar 

  20. Hsia J, Simon JA, Lin F et al. (2000) Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation 102: 2228–2232

    CAS  PubMed  Google Scholar 

  21. International Stroke Trial Collaborative Group (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 349: 1569–1581

    Article  PubMed  Google Scholar 

  22. Kannel WB, Shurtleff D (1973) The Framingham Study. Cigarettes and the development of intermittent claudication. Geriatrics 28: 61–68

    CAS  PubMed  Google Scholar 

  23. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham Study. JAMA 241: 2035–2038

    Article  CAS  PubMed  Google Scholar 

  24. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F (1997) Body iron stores and the risk of carotid atherosclerosis. Prospective results from the Bruneck Study. Circulation 96: 3300–3307

    CAS  PubMed  Google Scholar 

  25. Kiechl S, Willeit J, Rungger G, Egger G, Oberhollenzer F, Bonora E (1998) Alcohol consumption and atherosclerosis: What is the relation? Prospective results from the Bruneck Study. Stroke 29: 900–907

    CAS  PubMed  Google Scholar 

  26. Kiechl S, Egger G, Mayr M et al. (2001) Chronic infections and the risk of carotid atherosclerosis. Prospective results from a large population study. Circulation 103: 1064–1070

    CAS  PubMed  Google Scholar 

  27. Krauss RM, Eckel RH, Howard B et al. (2000) AHA Dietary Guidelines. Revision 2000. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102: 2284–2299

    CAS  PubMed  Google Scholar 

  28. Larsen OA, Lassen NA (1966) Effect of daily muscular exercise in patients with intermittent claudication. Lancet 2: 1093–1096

    Article  CAS  PubMed  Google Scholar 

  29. Malinow MR, Bostom AG, Krauss RM (1999) Homocysteine, diet, and cardiovascular diseases. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 99: 178–182

    CAS  PubMed  Google Scholar 

  30. Mas JL, Arquizan C, Lamy C et al. (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345: 1740–1746

    Article  CAS  PubMed  Google Scholar 

  31. Mohr JP, Thompson JLP, Lazar RM et al. (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345: 1444–1451

    Article  CAS  PubMed  Google Scholar 

  32. Mosca L, Collins P, Herrington DM et al. (2001) Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 104: 499–503

    CAS  PubMed  Google Scholar 

  33. Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF (1997) Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 96: 44–49

    CAS  PubMed  Google Scholar 

  34. Neumann FJ, Kastrati A, Miethke T (2001) Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3). A randomised, double-blind, placebo-controlled trial. Lancet 357: 2085–2089

    Article  CAS  PubMed  Google Scholar 

  35. Planas A, Clara A, Pou JM et al. (2001) Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men. Int J Obes Relat Metab Disord 25: 1068–1070

    Article  CAS  PubMed  Google Scholar 

  36. PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041

    Article  PubMed  Google Scholar 

  37. Ridker PM, Cushman M, Stampfer MJ (1997): Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973–979

    Article  CAS  PubMed  Google Scholar 

  38. Robless P, Mikhailidis DP, Stansby G (2001) Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 88: 787–800

    Article  CAS  PubMed  Google Scholar 

  39. Rosen H, Muhlestein JB, Bartlett J (2000) Collaborative multidisciplinary workshop report. Clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease. J Infect Dis 181: S582-S584

    Article  PubMed  Google Scholar 

  40. Rossouw JE, Anderson GL, Prentice RL et al. (2002) Writing Group for the Women’s Health Initiative Investigators; Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333

    CAS  PubMed  Google Scholar 

  41. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R (1992) High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86: 803–811

    CAS  PubMed  Google Scholar 

  42. Schnyder G, Roffi M, Pin R et al. (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345: 1593–1600

    Article  CAS  PubMed  Google Scholar 

  43. Schrader J, Luders S, Kulschewski A et al. (2003) The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 34: 1699–1703

    Article  PubMed  Google Scholar 

  44. Sever PS, Dahlof B, Poulter NR et al. (2003) ASCOT investigators; Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149–1158

    Article  CAS  PubMed  Google Scholar 

  45. Stephens NG, Parsons A, Schofield PM et al. (2001) Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358: 527–533

    Article  PubMed  Google Scholar 

  46. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ (1996) Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781–786

    Article  CAS  PubMed  Google Scholar 

  47. Third report of the National Cholesterol Education Program (NCEP) Expert Panel (2001) Detection, evaluation, and treatment of high blood cholesterol in adults. NIH Publication 1: 3670

    Google Scholar 

  48. Toole JF, Malinow MR, Chambless LE et al. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291: 565–575

    Article  CAS  PubMed  Google Scholar 

  49. Turnbull F (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists‘ Collaboration. Lancet 362: 1527–1535

    Article  CAS  PubMed  Google Scholar 

  50. UK Prospective Diabetes Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865

    Article  PubMed  Google Scholar 

  51. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703–713

    PubMed  Google Scholar 

  52. Vane JR, Meade TW (1997) Second European Stroke Prevention Study (ESPS 2): clinical and pharmacological implications. J Neurol Sci 145: 123–125

    Article  CAS  Google Scholar 

  53. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345: 1243–1249

    Article  CAS  PubMed  Google Scholar 

  54. Willeit J (2001) Stroke control. Wien Klin Wochenschr 113: 80–83

    CAS  PubMed  Google Scholar 

  55. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study. N Engl J Med 342: 145–153

    Article  CAS  PubMed  Google Scholar 

  56. Zacharski LR, Chow B, Lavori PW et al. (2000) The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 139: 337–345

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Keine Angaben

Author information

Authors and Affiliations

  1. Universitätsklinik für Neurologie, Innsbruck

    S. Kiechl

  2. Universitätsklinik für Gefäßchirurgie, Innsbruck

    J. Falkensammer

  3. Universitätsklinik für Chirurgie, Klinische Abeilung für Gefäßchirurgie, Anichstraße 35, 6020, Innsbruck, Österreich

    J. Falkensammer

Authors
  1. S. Kiechl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Falkensammer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Falkensammer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kiechl, S., Falkensammer, J. Prävention der Atherosklerose bei gefäßchirurgischen Patienten. Gefässchirurgie 9, 172–179 (2004). https://doi.org/10.1007/s00772-004-0353-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00772-004-0353-4

Schlüsselwörter

Keywords

Search

Navigation